Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Fluconazole, Bupropion, or Itraconazole on BMS-986235 PK
NCT04464577Phase 1Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BMS-986235 in heart failure (HF) and myocardial infarction (MI) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Area under the plasma concentration-time curve from time 0 to time of last quantifiable concentration of BMS-986235 with fluconazole at Day 12, Maximum plasma concentration of BMS-986235 with fluconazole at Day 12 and 10 more. Planned start Apr 2021; status: withdrawn.
02
Drugs
BMS-986235
03
Conditions
heart failure (HF)myocardial infarction (MI)
Beyond the preview
Go deeper on NCT04464577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04464577.